Taysha Gene Therapies, Inc.·4

Jan 14, 4:45 PM ET

Alam Kamran 4

4 · Taysha Gene Therapies, Inc. · Filed Jan 14, 2026

Insider Transaction Report

Form 4
Period: 2026-01-12
Alam Kamran
CHIEF FINANCIAL OFFICER
Transactions
  • Award

    Common Stock

    [F1]
    2026-01-12+359,0001,546,603 total
  • Award

    Employee Stock Option (right to buy)

    [F2]
    2026-01-12+231,000231,000 total
    Exercise: $4.86Exp: 2036-01-12Common Stock (231,000 underlying)
Footnotes (2)
  • [F1]Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
  • [F2]25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Signature
/s/ Kamran Alam, Attorney-in-Fact|2026-01-14

Documents

1 file
  • 4
    form4-01142026_040105.xmlPrimary